Related Experiment Video

Updated: May 7, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Importance of achieving the composite endpoints in diabetes

Ambika Gopalakrishnan Unnikrishnan1, Arpandev Bhattacharyya, Manash Pratim Baruah

  • 1Department of Clinical Endocrinology, Chellaram Diabetes Institute, Budruk, Pune, Maharashtra, India.

Indian Journal of Endocrinology and Metabolism
|October 2, 2013
PubMed

Insights

Composite endpoints (CEPs) improve clinical trial efficiency by assessing net clinical benefit and reducing sample sizes. However, careful construction and reporting are crucial for accurate interpretation of therapeutic effects.

Area of Science:

  • Clinical Trials
  • Pharmaceutical Research
  • Biostatistics

Background:

  • Randomized controlled trials (RCTs) are crucial for evaluating new drug safety and efficacy.
  • High costs and scientific effort are associated with acquiring trial data.
  • Composite endpoints (CEPs) are recommended over individual endpoints for assessing overall disease control.

Purpose of the Study:

  • To highlight the benefits of using composite endpoints in clinical trial design.
  • To address concerns regarding the interpretation of results from trials using CEPs.
  • To provide suggestions for constructing and reporting CEPs effectively.

Main Methods:

  • Review of guidelines and literature on clinical trial endpoint selection.
  • Analysis of the advantages of composite endpoints in various therapeutic areas, including diabetes.
  • Identification of potential challenges and biases associated with CEPs.

Main Results:

  • CEPs enhance the assessment of net clinical benefit and reduce required sample sizes.
  • CEPs can mitigate issues related to competing risks and single outcome validation.
  • Potential for misinterpretation exists if component differences or biases are not addressed.

Conclusions:

  • Composite endpoints offer significant advantages in clinical trial design and interpretation.
  • Clear guidelines for CEP construction and result reporting are essential for accurate understanding of intervention effects.
  • Further research and standardized methodologies can improve the utility of CEPs.
Keywords:
Diabetes mellitus type 2randomized controlled trials as topicresearch designtreatment outcome

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Complications of Diabetes Mellitus01:22

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.